I think many now consider me somewhat of a loose cannon on

New Post Public Reply Private Reply Replies (4) Message Board
petemantx
10,834
I think many now consider me somewhat of a loose cannon on the board but that is in no way my intention. I do, though, feel the board needs to address areas of concern and I have many. No longer am I of the opinion that "Leo will do it" with no discussion of whether he is doing a good job or not is something that is verboten on the board.

The PR a couple of days ago solidified IMO the many, many varied uses for Brilacidin against many viruses and bacteria, Covid still being a major player in this realm.

But the PR left me stone cold stunned with the following statements and made me wonder what the hell they have been doing for the last 8 months. The info in red below is right from the PR:

Efforts to advance the Brilacidin Oral Mucositis (OM) program are a key focus. The Company is presently exploring timelines and scenario planning—including the option to seek a meeting with the U.S. Food and Drug Administration towards the initiation of a Phase 3 clinical trial evaluating oral rinse Brilacidin as a new treatment for the prevention of OM in head and neck cancer patients receiving chemoradiation. Brilacidin oral formulation development work for Ulcerative Colitis continues. The Company has also been notified by Alfasigma, its licensing partner, of their intent to initiate this year Phase 2 testing of Brilacidin in Ulcerative Proctitis/Proctosigmoiditis.





1. We have been told a P3 for OM would begin Q1 '22 for quite sometime and now the company says they are JUST NOW planning a MEETING with the FDA for such a trial. JUST NOW A MEETING?"??"? All I can say is WTF happened? Isn't Brilacidin supposed to be Fast Tracked??? And yet a year or so after the P2 we feel a meeting is now a possibility to discuss a P3? To me this is gross incompetence at best as the P3 is most likely now lucky to get started by late '22.

2. The pill for IBD without the special sauce from BDD still in the works though that was deemed not that hard when IPIX decided to go this new route. So basically next to nothing for IBD has been done in the last year and since we will need a P1 for the pill prior to a P2 or even if they allow a P1/P2 to be run together i again feel we are looking at the end of '22 at best for such a trial to begin. I take it someone is helping us formulate this pill - are they a 2 person company as well because they also seem not to be able to move things past the starting line.

3. AlphaSigma - All they had to do was come up with a gel/foam/ etc and here we are about 2 years down the road and they sit at square 1 with the Q1 '22 planned P2 now moved out to sometime this year, again I consider that most likely the end of the year. Did Covid wipe out all cases of postsigmoid colitis to move the clock back so drastically ??? I think not. So IMO this supposedly decent sized pharma is no better than IPIX in getting things moving.

I know this post will piss off most people but if so, tell me what I am missing.

Makes me also wonder why we even have a rental space in Watertown MA since nobody is there, at least I hope no one is there as there is no need for them)

So as to the PR - yeah, the trial data improved greatly but what we were told in the PR makes me think we haven't got jack **** going on in the only area that could quickly change our fortunes as to being able to raise money.

As to the raising funds question, Brilacidin hasn't proved itself yet to the powers to be (BARDA, INH, etec) to at least have gotten us in the pool for possible funds. Again, we are planning to submit to a number of different govt sources for funds. NO ACTION HAS HAPPENED, we just again are planning.

So WTF has been happening to progress our company on any front?
The talk about purchasing additional assets IMO makes it sound like we have a crazy "Putin" type character at the helm divorced from reality.

I don't feel I am being overly critical because IMO NOTHING has been accomplished in quite awhile while everybody is still getting paid handsomely as though they are breaking their asses getting things done.







1

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Community Heritage Financial Declares Q3 2026 Dividend

Updated Category News Views 6

Dividend Declared Amidst Challenging Times There's nothing quite like the ringing of a cash register, and for Community Heritage Financial, Inc. (OTCID: CMHF), that's what an $0.08 per share dividend feels like. Declared for the third quarter of 2026, this payout is set to line the pockets of shareholders who made the cut by October 30, 2026. The folks waiting for their...

Continue Reading
New JPA Aims to Energize Inland Empire's Water Supply

Updated Category News Views 25

Fresh Steps in San Bernardino's Infrastructure Strategy Here's a twist for you: public agencies in San Bernardino County decided enough with the same old, same old and cooked up a new joint powers authority (JPA). They call it the San Bernardino Water and Power Authority, which sounds snappy enough for a meeting room nameplate, I reckon. Who's Steering the Ship? Leading...

Continue Reading
Baidu Faces Class Action: Investors Push Against Fraud Allegations

Updated Category News Views 13

Baidu Under Fire for Alleged Misleading Statements Here's a fresh slice of drama straight outta the corporate trenches: Baidu, Inc. (NASDAQ: BIDU) finds itself tangled in a securities fraud lawsuit that’s causing a ruckus across investor circles. Schall, Brown & Schwartz LLP, those heavyweight gladiators in shareholder rights, are calling on grieved investors to step up...

Continue Reading
Firmable's Tech Intelligence: New Edge in B2B Sales

Updated Category News Views 16

New Era for B2B Sales Teams Once again, the B2B sales landscape is getting a jolt—especially for those who’ve been fumbling in the dark pitching to prospects without any real idea of their tech environment. With the introduction of Firmable's Tech Intelligence, those blind days just got a lot brighter. By offering detailed insights into what technologies a company is...

Continue Reading
Endava Faces Securities Fraud Lawsuit: Investor Implications

Updated Category News Views 7

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...

Continue Reading
Standex's New Financial Lead: Stoddard Takes Helm

Updated Category News Views 9

New Financial Captain Aboard Standex's Ship Alright, here's something that'll have investors nodding along with interest: Standex International has just named Samantha L. Stoddard as their incoming Chief Financial Officer and Treasurer, effective December 1, 2026. Now, Standex isn't some scrappy upstart. We're talking about a veteran manufacturer intricately working...

Continue Reading
National Showrooms Expands into Virginia with Key Buy

Updated Category News Views 8

A New Chapter for Greenwich Kitchens I'll tell you what's catching my eye this time—National Kitchen & Bath Showrooms are making their move into Virginia by snapping up Greenwich Kitchens, a well-regarded name in the local kitchen and bath scene. Founded back in '78, Greenwich Kitchens has been a staple in the Virginia Beach and Hampton Roads areas for nearly half a...

Continue Reading
OppFi Readies Q3 Earnings; Investors Eye Financials

Updated Category News Views 8

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

Continue Reading
Roof Inspections: Richmond's Key to Home Longevity

Updated Category News Views 13

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

Continue Reading
VISTAR Oakland Workers Join Teamsters for Unity

Updated Category News Views 10

Warehouse Workers Break Free from the Shackles Ever had that feeling, where enough is enough? That's where 37 warehouse workers at VISTAR find themselves, shaking off the dust and signing up with Teamsters Local 853. This ain't just a fleeting wind of change; it's the whole damn storm. Turning Points and Union Victories Think about it. This move by the VISTAR warehouse...

Continue Reading

Top 5 Most Recently Viewed Articles

Pre® Brands Expands Grass-Fed Beef Range in BJ's Clubs

Updated Category News Views 280

Pre® Brands Expands Grass-Fed Beef Offerings Pre® Brands, a prominent name in grass-fed and grass-finished premium lean beef, has broadened its product line to include various healthier beef options at all BJ's Wholesale Club locations. This strategic move introduces three new exclusive products to the existing selections of better-for-you steaks, ground beef, and stew...

Continue Reading
Analyzing Intel's Market Sentiment: A Shift in Short Interest

Updated Category News Views 168

Understanding Intel's Short Interest Movement Recently, Intel's short percent of float has experienced a notable decrease, falling by 10.55% since its last report. Currently, the company has approximately 107.68 million shares sold short, accounting for 2.46% of all shares available for trade. This translates to an estimated average of 1.0 days traders would need to cover...

Continue Reading
Allisha Gray and MyEyeDr. Promote Eye Health for Students

Updated Category News Views 63

Promoting Eye Health Among Students Recently, MyEyeDr., a notable provider of eye health care, joined forces with WNBA star Allisha Gray to enhance awareness of eye health among students. This collaboration shines a light on the significance of proper vision care for youth, particularly at-risk students who may lack access to essential health services. ExamJam Event...

Continue Reading
Lovesac's Journey to Becoming America's Favorite Home Brand

Updated Category News Views 275

Building a Brand with Heart Shawn Nelson transformed his passion for oversized bean bag chairs into a thriving business with The Lovesac Co. (NASDAQ: LOVE). This journey began as a side project in college and has evolved into a publicly listed home brand. Nelson describes his success as a result of creating his own opportunities. The Road to Success In a recent...

Continue Reading
S&P 500 Soars to New Heights Amid Federal Reserve Anticipations

Updated Category News Views 46

S&P 500 Hits New Record Highs The S&P 500 index has recently reached some impressive milestones, hitting new record highs during trading sessions. It closed up by 0.04%, marking its strong seventh day of consecutive gains. Traders are keeping a close eye on how market dynamics unfold as we approach a pivotal decision from the Federal Reserve. Current Market Landscape This...

Continue Reading